rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
5
|
pubmed:dateCreated |
2006-5-12
|
pubmed:abstractText |
Aspirin increases fibrin clot porosity and susceptibility to lysis. It is unknown whether other drugs, in combination with aspirin, used in the treatment of coronary artery disease (CAD) might affect clot structure and resistance to lysis.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1538-7933
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1029-36
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:16689755-Aged,
pubmed-meshheading:16689755-Coronary Artery Disease,
pubmed-meshheading:16689755-Fenofibrate,
pubmed-meshheading:16689755-Fibrinolysis,
pubmed-meshheading:16689755-Genotype,
pubmed-meshheading:16689755-Heptanoic Acids,
pubmed-meshheading:16689755-Humans,
pubmed-meshheading:16689755-Male,
pubmed-meshheading:16689755-Permeability,
pubmed-meshheading:16689755-Pyrroles,
pubmed-meshheading:16689755-Simvastatin,
pubmed-meshheading:16689755-Tetrahydroisoquinolines,
pubmed-meshheading:16689755-Thrombin,
pubmed-meshheading:16689755-Thrombosis
|
pubmed:year |
2006
|
pubmed:articleTitle |
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
|
pubmed:affiliation |
Department of Medicine, Jagellonian University School of Medicine, 8 Skawinska Str., 31-066 Krakow, Poland.
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|